Pulished Date October, 2018
ID: 7839
Share on
Share on

Asia-Pacific Non-Insulin Diabetes Therapies Market By Drug Type (Sulphonylureas , Amylin Agonists, GLP-1 Agonists & Analogs , Biguanides , Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors , Alpha-Glucosidase Inhibitors , Dipeptidyl Peptidase-4 (DPP4) Inhibitors, Thiazolidinediones (or Glitazones Or TZDs), Glinides Or Meglitinides, By Region- Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023).

Pulished: October, 2018
ID: 7839
Pages: 145

Asia-Pacific Non-Insulin Diabetes Therapies market revenue was near to USD 6.09 million in 2018 and is expected to grow at a CAGR of 7.62% to reach USD 8.54 million by 2023.

Non-Insulin Diabetes occurs due to metabolic disorders and the main symptoms are high levels of sugar in blood, low levels of insulin. The main reasons for the up growth of this market are: food habits, increasing urbanisation resulting in cultural changes rapidly, different lifestyles. These are the factors resulting the growth of Type-2 Non-Insulin Diabetes Therapies.

The market is segmented mainly by drug type. By drug type market is categorised by  Sulphonylureas, Amylin Agonists, GLP-1 Agonists & Analogs , Biguanides , Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors , Alpha-Glucosidase Inhibitors , Dipeptidyl Peptidase-4 (DPP4) Inhibitors, Thiazolidinediones (or Glitazones or TZDs), Glinides or Meglitinides .Non-Insulin Diabetes Medication market is anticipated to experience a higher CAGR in coming days, because of the increase in the percentage of people affected by Type-2 Diabetes. Several companies and Industries have been working to find the appropriate medication without causing any side effects. Nowadays pharma companies are trying to adopt methods and produce drugs which when injected into the body enables liver to produce Insulin. Companies which are producing effective medicines for Non-Insulin Diabetes are also increasing their market value in a good pace. These are called non-Insulin Diabetes Medication. Non-Insulin Diabetic therapies are mostly oral based therapies; this is prescribed prior to using insulin in the line of therapy. Till 2016 most of the medications available for Diabetes are Insulin based and recent research shows us by 2023 more than 40% of the medications available in the market will be non- insulin products.

By geography the Asia-Pacific market is segmented into India, China, Korea, Japan and others. China got more diabetics than any other country in the world, which surpassed India in the recent past. In India about 62 million people are facing problems related to Diabetics. . Because of growth in number of people facing diabetic problems, the growth in this market is expected to increase exponentially in coming years.

Best companies treating Diabetes in the market include Tobira (New Jersey), Eli Lilly and Sumitomo Dainippon Pharma (Japan), Novo Nordisk (Denmark), Takeda (Japan), Sanofi (china), Mannkind (California), Bristol-Myers Squibb (New York), Astrazeneca (U.K), Boehringer Ingelheim (Germany), Bayer (Germany).

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Type                   

                                5.1.1 Introduction           

                                5.1.2 Sulphonylureas     

                                5.1.3 Amylin Agonists    

                                5.1.4 GLP-1 Agonists & Analogs

                                5.1.5  Biguanides             

                                5.1.6 Glinides & Meglinitides      

                                5.1.7 Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors              

                                5.1.8 Thiazolidinediones (or Glitazones or TZDs 

                                5.1.9 Alpha-Glucosidase Inhibitors          

                                5.1.10 Dipeptidyl Peptidase-4 (DPP4) Inhibitors

                                5.1.11 Y-o-Y Growth Analysis, By Drug Type        

                                5.1.12 Market Attractiveness Analysis, By Drug Type      

                                5.1.13 Market Share Analysis, By Drug Type        

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Type

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Type

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Product

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Tobira                           

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novo Nordisk                            

                8.3 Takeda and Sanofi                   

                8.4 Eli Lilly Sumitomo Dainippon Pharma                               

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Drug, by  Region along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Asia Pacific Non-Insulin Diabetes Therapy Market Market By Drug Type, From 2018-2023 ( USD Million )
  2. Asia Pacific Sulphonylureas Market By Region, From 2018-2023 ( USD Million )
  3. Asia Pacific Amylin Agonists Market By Region, From 2018-2023 ( USD Million )
  4. Asia Pacific GLP-1 Agonists & Analogs  Market By Region, From 2018-2023 ( USD Million )
  5. Asia Pacific  Biguanides  Market By Region, From 2018-2023 ( USD Million )
  6. Asia Pacific Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors  Market By Region, From 2018-2023 ( USD Million )
  7. Asia Pacific Alpha-Glucosidase Inhibitors  Market By Region, From 2018-2023 ( USD Million )
  8. Asia Pacific Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market By Region, From 2018-2023 ( USD Million )
  9. Asia Pacific Glinides or Meglitinides ! Market By Region, From 2018-2023 ( USD Million )
  10. Asia Pacific Thiazolidinediones or Glitazones or TZDs Market By Region, From 2018-2023 ( USD Million )
  11. Japan Non-Insulin Diabetes Therapy Market Market By Drug Type, From 2018-2023 ( USD Million )
  12. China Non-Insulin Diabetes Therapy Market Market By Drug Type, From 2018-2023 ( USD Million )
  13. India Non-Insulin Diabetes Therapy Market Market By Drug Type, From 2018-2023 ( USD Million )
  14. Australia Non-Insulin Diabetes Therapy Market Market By Drug Type, From 2018-2023 ( USD Million )
  15. South Korea Non-Insulin Diabetes Therapy Market Market By Drug Type, From 2018-2023 ( USD Million )

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Request Sample